ALFA Finder| Value | ₹20.50 Cr |
|---|---|
| Execution period | 30 days |
BSE filing, NSE: AGARWALEYE. Summary written from the filing by ALFA Finder's alert engine.
Dr. Agarwals Health Care Ltd: key numbers
- Share price
- ₹553.60
- Market cap
- ₹17,555 Cr
- Revenue (annual)
- ₹2,080 Cr
- Net profit (annual)
- ₹133.2 Cr
- P/E (TTM)
- 101.2×Sector 54.5×
- Promoter holding
- 32.33%-0.01% QoQ
- FII holding
- 49.56%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Agarwals Health Care Ltd
All →Dr. Agarwals Health Care Other Announcement
Dr. Agarwal's Health Care submitted ICRA's monitoring agency report for the quarter ended September 30, 2026. ICRA reports no material deviation in IPO proceeds utilisation.
Dr. Agarwals Health Care Employee Stock Options
Dr. Agarwal's Health Care allotted 54,728 equity shares to employees on exercise of ESOP 2022 options. Paid-up capital rose to 31,70,99,111 shares, with no cash consideration stated.
Dr. Agarwals Health Care Earnings Call Transcript: Key Takeaways
Q2 FY27 revenue ₹655 Cr (+31.4% YoY) and PAT ₹57 Cr (+55.8%), network-led growth; India EBITDA margin flat near 28%.
Dr. Agarwals Health Care Management Change
Dr Agarwals Health Care reports Mr. Amar Agarwal's redesignation from Chairman and Non-Executive Director to Executive Director, effective 1 November 2026. The change was approved at a board meeting held on 5 November 2026.
Dr. Agarwals Health Care Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹655 Cr (+31.4% YoY) and PAT ₹57 Cr (+55.8%). H1 FY27 revenue ₹1,269 Cr (+28.7%), PAT ₹112 Cr (+50.1%). Strategy is aggressive facility expansion, with 65 FY27E additions.
Dr. Agarwals Health Care Financial Results
Dr. Agarwal's H1 FY27 revenue rose 28.7% to Rs 1,269 crore; PAT rose 50.1% to Rs 112 crore. Amar Agarwal's executive chairman appointment awaits postal ballot approval.
Other legal & regulatory announcements
All →iSERA Lifesciences Legal & Regulatory
iSERA Lifesciences disclosed a SEBI warning letter for non-filing of Reg 7(3), 13(3) and 47. No financial or operational impact is stated.
The Grob Tea Company Legal & Regulatory
Grob Tea discloses a pending arbitration and NCLT case against Larica LED Products for Rs. 2.26 Crore recovery. The dispute arose under a consortium agreement for onward supply to PSUs.
- Value
- ₹2.26 Cr
Sapphire Foods India Legal & Regulatory
Sapphire Foods received a rectified GST order confirming a ₹4.39 Cr tax demand from Karnataka. The demand increased from the earlier ₹3.07 Cr figure.
- Value
- ₹4.39 Cr
B L Kashyap & Sons Legal & Regulatory
Board noted NSE's ₹48,000 fine for delayed Q2 shareholding pattern filing under Regulation 31. Company paid the fine and directed stronger compliance controls.
- Value
- ₹0.00 Cr
Sterling and Wilson Renewable Energy Legal & Regulatory
SWSOLAR's ICC arbitration with TSGF SPA extended until March 31, 2027. A conditional settlement was executed with no financial impact until implementation.
Committed Cargo Care Legal & Regulatory
Supreme Court upheld NCLT order directing CCCL's directors to personally pay ₹2 Crore to Stockflow's estate. No liability attaches to the Company itself.
- Value
- ₹2.00 Cr